Charles Schwab Investment Management Inc Entrada Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 185,259 shares of TRDA stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
185,259
Previous 203,693
9.05%
Holding current value
$1.57 Million
Previous $1.37 Million
21.49%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding TRDA
# of Institutions
117Shares Held
27.9MCall Options Held
13.7KPut Options Held
14K-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.6MShares$13.6 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $266M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...